Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy
- 29 August 2023
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (10) , 1086-1098
Abstract
Summary: Background: Hepatitis B surface antigen (HBsAg) seroclearance marks regression of hepatitis B virus (HBV) infection. However, more than one‐fifth of patients with functional cure following pegylated interferon‐based therapy may experience HBsAg seroreversion. The mechanisms causing the HBV relapse remain unclear.Aim: To investigate the level and origin of HBV transcripts in patients with functional cure and their role in predicting relapse.Methods: Liver tissue obtained from patients with functional cure, as well as uncured and treatment‐naïve HBeAg‐negative patients with chronic hepatitis B (CHB) were analysed for intrahepatic HBV markers. HBV capture and RNA sequencing were used to detect HBV integration and chimeric transcripts.Results: Covalently closed circular DNA (cccDNA) levels and the proportion of HBsAg‐positive hepatocytes in functionally cured patients were significantly lower than those in uncured and treatment‐naïve HBeAg‐negative patients. Integrated HBV DNA and chimeric transcripts declined in functionally cured patients compared to uncured patients. HBsAg‐positive hepatocytes present in 25.5% of functionally cured patients, while intrahepatic HBV RNA remained in 72.2%. The levels of intrahepatic HBV RNA, integrated HBV DNA, and chimeric transcripts were higher in functionally cured patients with intrahepatic HBsAg than in those without. The residual intrahepatic HBsAg in functionally cured patients was mainly derived from transcriptionally active integrated HBV DNA; meanwhile, trace transcriptional activity of cccDNA could also remain. Two out of four functionally cured patients with intrahepatic HBsAg and trace active cccDNA experienced HBV relapse.Conclusion: Integrated HBV DNA and cccDNA maintain transcriptional activity and maybe involved in HBsAg seroreversion in intrahepatic HBsAg‐positive patients with functional cure and linked to virological relapse.Keywords
Funding Information
- National Basic Research Program of China (2021YFA1103000, 2021YFA1302000)
- National Natural Science Foundation of China (82170612: 81672701 : 82070611 : 82173064: 81971481)
- Guangzhou Municipal Science and Technology Program key projects (2023B01J1007)
This publication has 41 references indexed in Scilit:
- HBV DNA Integration: Molecular Mechanisms and Clinical ImplicationsViruses, 2017
- Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissueInternational Journal of Cancer, 2017
- Genomic and oncogenic preference of HBV integration in hepatocellular carcinomaNature Communications, 2016
- Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinomaJournal of Hepatology, 2016
- Clinical Relevance of HLA Gene Variants in HBV InfectionJournal of Immunology Research, 2016
- DriverDBv2: a database for human cancer driver gene researchNucleic Acids Research, 2015
- The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinomaJournal of Hepatology, 2014
- HIVID: An efficient method to detect HBV integration using low coverage sequencingGenomics, 2013
- Clonal Expansion of Normal-Appearing Human Hepatocytes during Chronic Hepatitis B Virus InfectionJournal of Virology, 2010
- The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte responseNature Medicine, 1996